NOVEL has led 300+ Projects, Won 15+ Awards and Nominations
Recognized Leader for Drug & Device Strategy
NOVEL Health Strategies is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. NOVEL's team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. NOVEL has large network of internal and external stakeholders and has published several thought leading strategy perspectives.
Our Team in News
During 2011-19 NOVEL's team was interviewed and quoted by The New York Times, Scientific American, Fast Company and Nature Medicine.
Our team has published over 300 studies in healthcare. These studies have been cited by hundreds of publications.
We have presented trends, views and studies at conferences, federal agency meetings and special workshops.
NOVEL Selected for 23 Presentations at ISPOR Baltimore
NOVEL was selected for 23 peer-reviewed presentations at ISPOR Baltimore. NOVEL was also selected for PODIUM session and two award-finalists. Watch 1 minute Replay of our Podium Presentation.
Indirect Treatment Comparison by NOVEL for a breakthrough therapy (NEW)
NOVEL recently published an indirect treatment comparison for a breakthrough therapy for tardive dyskinesia
AWARD Winning Study on Market Access Trends by NOVEL
NOVEL's team recently conducted a comprehensive study on market access trends of Top 100 selling drugs. This study won PLATINUM medal by AMCP and was also nominated by ISPOR as award finalist.
Annual Strategy Perspective in Nature Biotechnology
Our annual strategy series has been cited and quoted more than two hundred times. This series was published in Nature Biotechnology (Journal Impact Factor 30+).
Market Access & Reimbursement Strategy Seminar in Copenhagen
NOVEL's team and leading stakeholders hosted a 1 day workshop on Market Access & Reimbursement Strategy in Copenhagen.